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important epidemiological and economic burden, literature on cost of chemother-
apy in breast cancer is rather scarce in Germany. The objective of this study was to
estimate the cost of adjuvant chemotherapy in early stage breast cancer in Ger-
many, using two different perspectives: the sick funds and the society. METHODS:
A semi-systematic search of the literature was conducted to identify relevant ar-
ticles describing the cost of adjuvant chemotherapy in Germany. The electronic
database Pubmed and a selection of congress databases were searched using com-
binations of search terms designed to identify publications describing cost of ad-
juvant chemotherapy in early stage breast cancer patients. Searches were limited
to those published in the English and German language between January 2000 and
April 2011. A retrospective multicentre study was conducted to collect chemother-
apy-related resources used. Unit costs were collected from public sources (EBM
catalogue, Rote list, DRG list). Cost items collected included: chemotherapy drugs,
monitoring and administration, prevention and management of adverse events,
transportation to the treatment centre, and when using the societal perspective,
also sick leaves. RESULTS: A total of 51 patients were included the study. The
following adjuvant chemotherapy regimens were given to the patients: TAC (22%),
FEC (20%), FECDOC (20%), TC (20%), ECDOC/PAC (12%) and others (8%). The
average total costs for an adjuvant chemotherapy treatment were estimated to be
€11,036 in a sick fund perspective and €16,199 in a broader societal perspective. The
direct costs were €5722 for chemotherapy drugs, €982 for chemotherapy adminis-
tration and monitoring, €4228 for supportive drugs and management of adverse
events. The indirect costs of sick leaves were €5163. CONCLUSIONS: Adjuvant
chemotherapy represents a significant economic burden to the health care system
and the society.
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OBJECTIVES: Oral oncologic therapies increasingly are becoming part of treatment
options for cancer. These agents often fall within the pharmacy benefit, with the
potential for increased out-of-pocket payments (OOPP) for patients. This study
evaluated patient OOPP for oral oncologic therapies in US managed care plans.
METHODS: Patients aged 18 years with 1 of 22 oral oncologics (altretamine, bex-
arotene, capecitabine, cyclophosphamide, dasatinib, erlotinib, etoposide, everoli-
mus, gefitinib, imatinib, isotretinoin, lapatinib, lenalidomide, leucovorin, nilotinib,
sorafenib, sunitinib, temozolomide, thalidomide, topotecan, tretinoin, vorinostat)
were identified in 2009 from a nationally-representative medical and pharmacy
claims database of over 100 US health plans. OOPP were calculated as the allowed
amount (dollars a health plan allows for a therapy, including member liability)
minus the paid amount (dollars paid by a health plan for a therapy). Mean/median
per-claim OOPP were reported for each oral therapy and stratified by geographic
region, health plan type, and payer type. RESULTS:A total of17,483 patients with at
least 1 oral oncologic were identified in 2009. Mean age was 38 years, 44% were
male, and 82% had a commercial payer. Per-claim OOPP for the 22 oral oncologics
varied. Median OOPP ranged from $0 (altretamine) to $42 (bexarotene); average
OOPP were $9 (leucovorin) to $523 (dasatinib). Overall, 79% of patients were paying
$50 or less per claim; 13% were paying $100 per claim. Among the majority of
therapies, the highest average OOPP were found in the Northeast and South. PPO
and indemnity plans had the largest OOPP for almost two-thirds of the therapies.
Medicare Risk (private Medicare) and self-insured patients had higher OOPP for
most therapies compared to commercial payers and Medicaid. CONCLUSIONS:
OOPP in the United States differ among oral oncologic options and confirm previ-
ous findings. As costs for therapy become a greater part of treatment decisions, an
understanding of the cost burden to patients will be critical in informing choices.
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OBJECTIVES: The major aims of the current research are to learn the average costs
of treatment of multiple myeloma (MM) in Ukraine. According to the world statis-
tics 30 new cases are registered annually per 1 million of population. In Ukraine
there are 4,434 cases of MM registered; these patients receive compensation by the
government for only limited amounts of necessary medicines, with most medi-
cines being paid for by patients themselves. METHODS: A database containing
records from hospital cards (2006-2010) for patients with MM was analyzed retro-
spectively. The sample was composed of 98 patients, aged 29 to 81 (mean age 62.5,
s.d. 9,6; 35.6% males). Drug costs related to direct diagnosis and associated MM
diseases (e.g., anemia, bone damage) were calculated. RESULTS: The average an-
nual cost of pharmaceutical treatment for patients with MM was 518.27EUR
(1EUR11,371UAH on 20.06.2011). Accounting for the prevalence of MM in Ukraine
(4,434 cases), the total cost of treatment of MM in Ukraine is 2,297,984EUR. A sig-
nificant amount of these costs covers treatment of MM-associated bone disease,
resulting in an average annual cost of 70.76EUR for treatment of these disorders of
MM patients. From basic therapy the most expensive were treatment schemes with
bortezomib (6 patients). If patients who were treated with bortezomib are excluded
from the general pool, the total costs of drug treatment will be 107.68EUR from
which 64.08EUR will take treatment of bone disorders with biphosphonates. No
correlations were found between sex, age, date of diagnosis and costs of treatment.
CONCLUSIONS: Analysis of the treatment practice and costs for MM patients has
shown that treatment of MM with bortezomib, even though involving only a small
number of patients, and treatment of MM-related conditions within the majority of
patients takes the major part of total costs.
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OBJECTIVES: To estimate the cost of treatment of oncological pain with four strong
opioids (methadone, morphine, oxycodone, fentanyl) in the Brazilian private
healthcare system between January and December 2010. METHODS: A claims da-
tabase of over 57 HMOs was analyzed to recover combined use of strong opioids
and oncological treatments between January and December 2010. Records showed
expenditure with medications, materials, hospitalization, and procedures and
diagnostics. RESULTS: Over the one-year study period, 293,918 patients made use
of at least one of the four opioids. The total healthcare expenditure with these
patients was R$ 3,243,890,302.91 (R$ 11,036.72/patient/year). Around 53% of these
patients (157,104) made concomitant use of oncology treatments, representing
around 74% of the total costs (R$ 2,424,503,643.76), with an average cost of R$
15,432.48/patient/year. The remaining patients (136,814) had an average cost of R$
5.989,06 per patient/year. Within the oncology patient population, the total health-
care expenditure with the four opioids alone was R$ 5,203,001.81. Fentanyl was the
most commonly used opioid in about 66% of patients, followed by morphine (33%),
methadone (1%) and oxicodone (0,8%). Around 17% of the oncology patient popu-
lation made use of two or more opioids during the study period. CONCLUSIONS:
Pain treatment of oncology patients is more costly for private payers in Brazil when
compared with patients not receiving oncological treatment. Although 47% of pa-
tients were considered non-oncological, this is not certain as they could have re-
ceived oncological treatment outside the study period or in a provider not covered
by the database (e.g. public hospital). With about 17% of oncological patients re-
ceiving two or more opioid treatments with the 12 month period suggests opioid
rotation is common.
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OBJECTIVES: Chemotherapy is vital for breast cancer treatment, but early-onset
toxicities like neutropenia hinder chemotherapy administration, especially in the
elderly. Neutropenia also increases costs due to hospitalizations and aggressive
systemic antibiotics administration. Primary prophylactic (PP) use of granulocyte-
colony stimulating factors (G-CSF) helps prevent neutropenia. However, evidence
supporting the cost-effectiveness of PPG-CSF is not conclusive and ASCO guide-
lines state the need for establishing cost-savings in high-risk groups like the el-
derly. This study examined the effect of PPG-CSF administration at the start of
first-course chemotherapy on Medicare costs during the year following the start of
chemotherapy. METHODS: A retrospective observational study of patients newly
diagnosed with breast cancer, between 1994 to 2002, was conducted using the
SEER-Medicare. To account for non-random nature of observational data, a cova-
riate genetic matching technique was used to pre-process the data before perform-
ing parametric regression analysis to estimate the effect of PPG-CSF on costs. Log-
arithm of cost was used as the dependent variable. RESULTS: Administration of
PPG-CSF during the first-course of chemotherapy was associated with 57% increase
in costs during the study period, despite an 11% drop in neutropenia hospitaliza-
tion costs. Forty-one percent of the increase in costs is due to increase in chemo-
therapy costs during the year after the start of chemotherapy. CONCLUSIONS: A
significant part of increase in immediate medical costs in breast cancer patients
receiving PPG-CSF is due to the improvement in chemotherapy administration.
Thus, increase in short-term costs are not necessarily bad in patients receiving
PPG-CSF. Adequate chemotherapy administration during the first year of breast
cancer therapy has long been established to prevent future recurrences, reduce
mortality and reduce long-term breast cancer care costs. Accounting for long-term
savings due to recurrence and metastasis prevention, indirect patient-care costs,
and quality of life aspects, is extremely vital for cost-analyses in chronic diseases
like breast cancer.
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OBJECTIVES: To estimate clinical outcomes and cost-offset (cost-benefit) from a
societal perspective expected from human papilloma virus (HPV) vaccination in
the Moscow region (MR). METHODS: A static population model developed in MS
Excel was adapted to the MR setting. The model estimated the annual number of
abnormal Papanicolaou smear test (abnormal PAP), precancerous lesions (cervical
intraepithelial neoplasia (CIN)) and cervical cancer (CC) as well as costs (RUB) as-
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